-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, RJR7zRAD/aUKRX6x0r4dxK4JxG7KS1trOuhQfVz8+61K4h1IyTOx8Ikg2RJBoSU9 a4JphxUpVBFt+fkVTF95gw== 0001209191-08-018683.txt : 20080317 0001209191-08-018683.hdr.sgml : 20080317 20080317182940 ACCESSION NUMBER: 0001209191-08-018683 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20080313 FILED AS OF DATE: 20080317 DATE AS OF CHANGE: 20080317 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AVANIR PHARMACEUTICALS CENTRAL INDEX KEY: 0000858803 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330314804 STATE OF INCORPORATION: CA FISCAL YEAR END: 0930 BUSINESS ADDRESS: STREET 1: 101 ENTERPRISE STREET 2: SUITE 300 CITY: ALISO VIEJO STATE: CA ZIP: 92656 BUSINESS PHONE: 949-389-6700 MAIL ADDRESS: STREET 1: 101 ENTERPRISE STREET 2: SUITE 300 CITY: ALISO VIEJO STATE: CA ZIP: 92656 FORMER COMPANY: FORMER CONFORMED NAME: LIDAK PHARMACEUTICALS DATE OF NAME CHANGE: 19920703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kaye Randall CENTRAL INDEX KEY: 0001350416 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-15803 FILM NUMBER: 08694457 BUSINESS ADDRESS: BUSINESS PHONE: 858-622-5200 MAIL ADDRESS: STREET 1: 11388 SORRENTO VALLEY ROAD STREET 2: STE. 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 doc4.xml FORM 4 SUBMISSION X0202 4 2008-03-13 0 0000858803 AVANIR PHARMACEUTICALS AVNR 0001350416 Kaye Randall 101 ENTERPRISE, SUITE 300 ALISO VIEJO CA 92656 0 1 0 0 Chief Medical Officer Class A Common Stock 2008-03-13 4 F 0 1440 1.10 D 418172 I See footnote Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due upon the vesting of restricted stock award granted to the Reporting Person under the Issuer's 2005 Equity Incentive Plan. The shares surrendered were valued based on the closing price of the Issuer's Class A common stock on the vesting date. Includes shares of common stock underlying Restricted Stock Units granted to the Reporting Person, which are subject to certain vesting conditions. A total of 500 shares of Class A common stock are held indirectly by the reporting person, which consists of 250 and 250 shares held by each of the reporting person's son and daughter, respectively. The reporting person disclaims beneficial ownership of these shares. /s/ Christine Ocampo, by power of attorney 2008-03-17 EX-24.4_231805 2 attachment1.htm EX-24 DOCUMENT 
POWER OF ATTORNEY

The undersigned hereby constitutes and appoints each of Christine Ocampo and
Ryan Murr, the undersigned's true and lawful attorneys-in-fact to:

(1)	execute for and on behalf of the undersigned, in the undersigned's capacity
as an officer and/or director Avanir Pharmaceuticals (the "Company"), Forms 3, 4
and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934
(the "Exchange Act"), and the rules thereunder;

(2)	do and perform any and all acts for and on behalf of the undersigned which
may be necessary or desirable to complete and execute any such Form 3, 4 or 5,
complete and execute any amendment or amendments thereto, and timely file any
such form with the United States Securities and Exchange Commission and any
stock exchange or similar authority; and

(3)	take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.

      The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done pursuant to this power of attorney.  The undersigned acknowledges that the
foregoing attorneys-in-fact, in serving in such capacity at the request of the
undersigned, are not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 of the Exchange Act.

	This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
attorneys-in-fact.

	The undersigned has caused this Power of Attorney to be executed as of this
13th day of March, 2008.


/s/ Randall Kaye
Signature

Randall Kaye, M.D.
Print Name
-----END PRIVACY-ENHANCED MESSAGE-----